Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer
BACKGROUND Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen‐deprivation therapy (ADT) among races. METHODS The Surveillance, Epidemiology, and End Result...
Saved in:
| Published in | Cancer Vol. 123; no. 9; pp. 1536 - 1544 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.05.2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0008-543X 1097-0142 1097-0142 |
| DOI | 10.1002/cncr.30503 |
Cover
| Abstract | BACKGROUND
Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen‐deprivation therapy (ADT) among races.
METHODS
The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa‐specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race.
RESULTS
Of all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non‐Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P < .001; chi‐square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24‐25 months; P < .001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35‐40 months; P < .001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8‐72.9 months) and 57.6 months (95% confidence interval, 27.7‐57.6 months) in non‐Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial.
CONCLUSIONS
Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non‐Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017;123:1536–1544. © 2017 American Cancer Society.
Among patients diagnosed with distant, de novo, metastatic prostate cancer, Asian men have a superior outcome compared with men of other races. Furthermore, black men and non‐Hispanic white men have comparable outcomes when they receive treatment with androgen‐deprivation therapy or chemohormonal therapy. |
|---|---|
| AbstractList | Among patients diagnosed with distant, de novo, metastatic prostate cancer, Asian men have a superior outcome compared with men of other races. Furthermore, black men and non‐Hispanic white men have comparable outcomes when they receive treatment with androgen‐deprivation therapy or chemohormonal therapy. BACKGROUND Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen‐deprivation therapy (ADT) among races. METHODS The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa‐specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race. RESULTS Of all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non‐Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P < .001; chi‐square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24‐25 months; P < .001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35‐40 months; P < .001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8‐72.9 months) and 57.6 months (95% confidence interval, 27.7‐57.6 months) in non‐Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial. CONCLUSIONS Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non‐Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017;123:1536–1544. © 2017 American Cancer Society. Among patients diagnosed with distant, de novo, metastatic prostate cancer, Asian men have a superior outcome compared with men of other races. Furthermore, black men and non‐Hispanic white men have comparable outcomes when they receive treatment with androgen‐deprivation therapy or chemohormonal therapy. Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races.BACKGROUNDProstate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races.The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa-specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race.METHODSThe Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa-specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race.Of all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non-Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P < .001; chi-square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24-25 months; P < .001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35-40 months; P < .001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8-72.9 months) and 57.6 months (95% confidence interval, 27.7-57.6 months) in non-Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial.RESULTSOf all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non-Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P < .001; chi-square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24-25 months; P < .001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35-40 months; P < .001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8-72.9 months) and 57.6 months (95% confidence interval, 27.7-57.6 months) in non-Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial.Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non-Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017;123:1536-1544. © 2017 American Cancer Society.CONCLUSIONSAsian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non-Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017;123:1536-1544. © 2017 American Cancer Society. BACKGROUND Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races. METHODS The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa-specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race. RESULTS Of all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non-Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P<.001; chi-square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24-25 months; P<.001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35-40 months; P<.001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8-72.9 months) and 57.6 months (95% confidence interval, 27.7-57.6 months) in non-Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial. CONCLUSIONS Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non-Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017; 123:1536-1544. copyright 2017 American Cancer Society. Among patients diagnosed with distant, de novo, metastatic prostate cancer, Asian men have a superior outcome compared with men of other races. Furthermore, black men and non-Hispanic white men have comparable outcomes when they receive treatment with androgen-deprivation therapy or chemohormonal therapy. Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races. The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa-specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race. Of all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non-Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P < .001; chi-square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24-25 months; P < .001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35-40 months; P < .001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8-72.9 months) and 57.6 months (95% confidence interval, 27.7-57.6 months) in non-Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial. Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non-Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017;123:1536-1544. © 2017 American Cancer Society. BACKGROUND Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races. METHODS The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa-specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race. RESULTS Of all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non-Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P<.001; chi-square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24-25 months; P<.001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35-40 months; P<.001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8-72.9 months) and 57.6 months (95% confidence interval, 27.7-57.6 months) in non-Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial. CONCLUSIONS Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non-Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017;123:1536-1544. © 2017 American Cancer Society. Among patients diagnosed with distant, de novo, metastatic prostate cancer, Asian men have a superior outcome compared with men of other races. Furthermore, black men and non-Hispanic white men have comparable outcomes when they receive treatment with androgen-deprivation therapy or chemohormonal therapy. |
| Author | Pettaway, Curtis A. Carducci, Michael A. Bernard, Brandon Mitchell, Edith P. Sridhar, Srikala S. Sweeney, Christopher J. Nguyen, Paul L. Muralidhar, Vinayak Chen, Yu‐Hui |
| AuthorAffiliation | 2 Princess Margaret Cancer Centre, Toronto, Canada 4 MD Anderson Cancer Center, Houston, USA 5 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA 3 Sidney Kimmel Cancer Center at Jefferson University Hospitals, Philadelphia, USA 1 Dana-Farber Cancer Institute, Boston, USA |
| AuthorAffiliation_xml | – name: 4 MD Anderson Cancer Center, Houston, USA – name: 5 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA – name: 3 Sidney Kimmel Cancer Center at Jefferson University Hospitals, Philadelphia, USA – name: 1 Dana-Farber Cancer Institute, Boston, USA – name: 2 Princess Margaret Cancer Centre, Toronto, Canada |
| Author_xml | – sequence: 1 givenname: Brandon surname: Bernard fullname: Bernard, Brandon organization: Dana‐Farber Cancer Institute – sequence: 2 givenname: Vinayak surname: Muralidhar fullname: Muralidhar, Vinayak organization: Dana‐Farber Cancer Institute – sequence: 3 givenname: Yu‐Hui surname: Chen fullname: Chen, Yu‐Hui organization: Dana‐Farber Cancer Institute – sequence: 4 givenname: Srikala S. surname: Sridhar fullname: Sridhar, Srikala S. organization: Princess Margaret Cancer Center – sequence: 5 givenname: Edith P. surname: Mitchell fullname: Mitchell, Edith P. organization: Sidney Kimmel Cancer Center at Jefferson University Hospitals – sequence: 6 givenname: Curtis A. surname: Pettaway fullname: Pettaway, Curtis A. organization: The University of Texas MD Anderson Cancer Center – sequence: 7 givenname: Michael A. surname: Carducci fullname: Carducci, Michael A. organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins – sequence: 8 givenname: Paul L. surname: Nguyen fullname: Nguyen, Paul L. organization: Dana‐Farber Cancer Institute – sequence: 9 givenname: Christopher J. surname: Sweeney fullname: Sweeney, Christopher J. email: christopher_sweeney@dfci.harvard.edu organization: Dana‐Farber Cancer Institute |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28055108$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt1qFDEUx4NU7LZ64wPIgDciTj2ZJJvMjSCLH4WiIApeGTLZs07KTLImmZa98xF8Rp_EjNuKFhGvcsL5nT__83FEDnzwSMh9CicUoHlqvY0nDASwW2RBoZU1UN4ckAUAqFpw9vGQHKV0Xr6yEewOOWwUCEFBLcin03FrbK7CpsLce2dd3lXBV7nHKkzZhhHn3Ii-unS5L0E2KZvs7JOqD3EsTr5__ZbQJ5fdBVbbGOY0VtZ4i_Euub0xQ8J7V-8x-fDyxfvV6_rs7avT1fOz2nJFWa0ayzmsG-BrsBasRKGYbDesK52oTpo1lLDj2Am57JpCLIXk0lrTMIqdYsfk2V53O3Ujri36HM2gt9GNJu50ME7_mfGu15_DhRa8DAVkEXh0JRDDlwlT1qNLFofBeAxT0lS1kilOGf8PVAip1LKdVR_eQM_DFH2ZhKZt6XYpFWsK9eB3879cX2-pALAHbJluirjRZU1lB2HuxQ2agp4PQc-HoH8eQil5fKPkWvWvMN3Dl27A3T9IvXqzerev-QFKg8S2 |
| CitedBy_id | crossref_primary_10_7717_peerj_14500 crossref_primary_10_1002_pros_24148 crossref_primary_10_1080_15313204_2024_2443429 crossref_primary_10_3390_cancers14020407 crossref_primary_10_1111_iju_14595 crossref_primary_10_1016_j_eururo_2020_01_012 crossref_primary_10_1097_MJT_0000000000001085 crossref_primary_10_4103_aja_aja_64_21 crossref_primary_10_2196_49353 crossref_primary_10_1038_s41391_024_00815_1 crossref_primary_10_3389_fendo_2024_1338420 crossref_primary_10_3389_fmed_2020_576812 crossref_primary_10_1038_s41391_018_0097_y crossref_primary_10_1002_pros_24016 crossref_primary_10_1016_j_euo_2018_10_011 crossref_primary_10_1111_bju_14970 crossref_primary_10_1038_s41585_024_00953_0 crossref_primary_10_1186_s40959_022_00131_4 crossref_primary_10_1007_s00345_021_03720_7 crossref_primary_10_1016_j_clgc_2017_08_006 crossref_primary_10_1200_JCO_23_00949 crossref_primary_10_1158_1078_0432_CCR_18_1394 crossref_primary_10_1002_ptr_8017 crossref_primary_10_1016_j_urolonc_2020_08_018 crossref_primary_10_1007_s11255_021_03055_7 crossref_primary_10_1038_s41391_023_00710_1 crossref_primary_10_1002_pros_24069 crossref_primary_10_1111_iju_14135 crossref_primary_10_1002_pros_24206 crossref_primary_10_1038_s41391_020_00278_0 crossref_primary_10_1016_j_clon_2023_03_014 crossref_primary_10_1080_13557858_2024_2429416 crossref_primary_10_1016_j_clgc_2023_01_001 crossref_primary_10_1038_s41391_019_0193_7 crossref_primary_10_1093_jjco_hyac089 crossref_primary_10_1016_j_jss_2017_05_031 crossref_primary_10_1002_pros_24253 crossref_primary_10_1007_s10147_021_01931_x crossref_primary_10_1002_pros_23663 crossref_primary_10_1002_pros_24312 crossref_primary_10_1111_iju_13870 crossref_primary_10_1088_2057_1739_aaa00b crossref_primary_10_3389_fonc_2021_658331 crossref_primary_10_1038_s41585_022_00622_0 crossref_primary_10_1186_s40169_019_0247_4 crossref_primary_10_1016_j_brachy_2020_08_023 crossref_primary_10_1007_s11912_023_01399_0 crossref_primary_10_4103_UROS_UROS_11_18 crossref_primary_10_1007_s40615_024_02217_4 crossref_primary_10_1038_s41391_019_0184_8 crossref_primary_10_18632_aging_203158 crossref_primary_10_2196_49349 crossref_primary_10_1002_pros_23958 crossref_primary_10_1002_1878_0261_13511 crossref_primary_10_1038_s41585_021_00442_8 crossref_primary_10_4103_aja202320 crossref_primary_10_6004_jnccn_2019_7302 |
| Cites_doi | 10.1093/jjco/hyq167 10.1038/aja.2010.42 10.1002/cncr.28485 10.1002/ijc.23500 10.1016/j.urology.2004.05.024 10.1016/j.urology.2004.04.014 10.1111/j.1464-410X.2006.06201.x 10.1007/s00345-015-1621-5 10.1016/j.juro.2012.06.046 10.1016/j.urology.2008.01.026 10.1016/j.urolonc.2005.09.003 10.3322/caac.21254 10.1016/S0090-4295(99)00461-6 10.1002/cncr.27379 10.1590/S1677-5538.IBJU.2014.03.04 10.1056/NEJMoa1503747 10.7150/ijbs.8974 10.1111/j.1442-2042.2011.02895.x 10.1186/s13014-015-0470-0 10.47102/annals-acadmedsg.V39N6p466 10.1016/j.eururo.2015.11.005 |
| ContentType | Journal Article |
| Copyright | 2017 American Cancer Society 2017 American Cancer Society. |
| Copyright_xml | – notice: 2017 American Cancer Society – notice: 2017 American Cancer Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| DOI | 10.1002/cncr.30503 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Oncogenes and Growth Factors Abstracts MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0142 |
| EndPage | 1544 |
| ExternalDocumentID | PMC5400707 28055108 10_1002_cncr_30503 CNCR30503 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: U10 CA180867 – fundername: NCI NIH HHS grantid: U10 CA180858 – fundername: NCI NIH HHS grantid: U10 CA180802 – fundername: NCI NIH HHS grantid: UG1 CA233329 – fundername: NCI NIH HHS grantid: UG1 CA189828 – fundername: NCI NIH HHS grantid: U10 CA180794 – fundername: NCI NIH HHS grantid: U10 CA180820 |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AAQOH AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- AAYXX ACCFJ AEEZP AEQDE AEYWJ AFFNX AGHNM AGNAY AGYGG AI. AIWBW AJBDE C1A CITATION HF~ H~9 J5H N4W NEJ OHT RSU VH1 WHG Y6R YQJ ZXP CGR CUY CVF ECM EIF NPM 7TO 7U7 AAMMB AEFGJ AGXDD AIDQK AIDYY C1K H94 K9. NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c4813-82c440d204d0cc0c7e58379f3b0148b7ad03b0b4eb576b2c0c65747cca231eb83 |
| IEDL.DBID | DR2 |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Thu Aug 21 18:04:12 EDT 2025 Fri Jul 11 08:53:36 EDT 2025 Fri Jul 11 09:14:50 EDT 2025 Sat Jul 26 02:27:55 EDT 2025 Thu Apr 03 07:00:05 EDT 2025 Tue Jul 01 04:09:20 EDT 2025 Thu Apr 24 22:53:16 EDT 2025 Wed Jan 22 16:22:37 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | prostate cancer ethnicity race chemotherapy survival |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2017 American Cancer Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4813-82c440d204d0cc0c7e58379f3b0148b7ad03b0b4eb576b2c0c65747cca231eb83 |
| Notes | The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.30503 |
| PMID | 28055108 |
| PQID | 1920467832 |
| PQPubID | 2045183 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5400707 proquest_miscellaneous_1897384134 proquest_miscellaneous_1855788697 proquest_journals_1920467832 pubmed_primary_28055108 crossref_citationtrail_10_1002_cncr_30503 crossref_primary_10_1002_cncr_30503 wiley_primary_10_1002_cncr_30503_CNCR30503 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 1, 2017 |
| PublicationDateYYYYMMDD | 2017-05-01 |
| PublicationDate_xml | – month: 05 year: 2017 text: May 1, 2017 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2017 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2010; 12 2004; 64 2012; 188 2006; 97 2006; 24 2010; 39 2000; 55 2015; 65 2015; 373 2015; 10 2011; 41 2015 2016; 70 2008; 123 2008; 72 2014; 40 2014; 120 2011; 18 2012; 118 2016; 34 2014; 10 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 Chia SE (e_1_2_8_22_1) 2010; 39 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 |
| References_xml | – volume: 64 start-page: 738 year: 2004 end-page: 743 article-title: Racial disparity in clinical course and outcome of metastatic androgen‐independent prostate cancer publication-title: Urology. – volume: 64 start-page: 212 year: 2004 end-page: 217 article-title: Impact of race on survival in men with metastatic hormone‐refractory prostate cancer publication-title: Urology. – volume: 70 start-page: 256 year: 2016 end-page: 262 article-title: Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long‐term survival analysis of the randomized phase 3 GETUG‐AFU15 trial publication-title: Eur Urol. – volume: 41 start-page: 40 year: 2011 end-page: 51 article-title: Population‐based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study publication-title: Jpn J Clin Oncol. – volume: 72 start-page: 1287 year: 2008 end-page: 1292 article-title: Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups publication-title: Urology. – volume: 39 start-page: 466 year: 2010 end-page: 471 article-title: Incidence, mortality and 5‐year relative survival ratio of prostate cancer among Chinese residents in Singapore from 1968 to 2002 by metastatic staging publication-title: Ann Acad Med Singapore. – volume: 10 start-page: 155 year: 2015 article-title: Conditional cancer‐specific mortality in T4, N1, or M1 prostate cancer: implications for long‐term prognosis [serial online] publication-title: Radiat Oncol. – volume: 65 start-page: 5 year: 2015 end-page: 29 article-title: Cancer statistics, 2015 publication-title: CA Cancer J Clin. – volume: 12 start-page: 718 year: 2010 end-page: 727 article-title: Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre publication-title: Asian J Androl. – volume: 118 start-page: 4280 year: 2012 end-page: 4289 article-title: Explaining racial differences in prostate cancer mortality publication-title: Cancer. – volume: 34 start-page: 319 year: 2016 end-page: 327 article-title: Clinical outcomes and nadir prostate‐specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer publication-title: World J Urol. – volume: 55 start-page: 387 year: 2000 end-page: 390 article-title: Clinical characteristics in black and white men with prostate cancer in an equal access medical center publication-title: Urology. – volume: 18 start-page: 876 year: 2011 end-page: 881 article-title: Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA publication-title: Int J Urol. – volume: 97 start-page: 1190 year: 2006 end-page: 1193 article-title: Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men publication-title: BJU Int. – volume: 188 start-page: 1164 year: 2012 end-page: 1169 article-title: Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346) publication-title: J Urol. – volume: 40 start-page: 316 year: 2014 end-page: 321 article-title: A 10‐year analysis of metastatic prostate cancer as an initial presentation in an underserved population publication-title: Int Braz J Urol. – volume: 120 start-page: 818 year: 2014 end-page: 823 article-title: No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year period publication-title: Cancer. – volume: 373 start-page: 737 year: 2015 end-page: 746 article-title: Chemohormonal therapy in metastatic hormone‐sensitive prostate cancer publication-title: N Engl J Med. – volume: 24 start-page: 396 year: 2006 end-page: 402 article-title: Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE publication-title: Urol Oncol. – volume: 10 start-page: 643 year: 2014 end-page: 651 article-title: Androgen receptor mutations and polymorphisms in African American prostate cancer publication-title: Int J Biol Sci. – volume: 123 start-page: 430 year: 2008 end-page: 435 article-title: Investigating black‐white differences in prostate cancer prognosis: a systematic review and meta‐analysis publication-title: Int J Cancer. – year: 2015 – ident: e_1_2_8_19_1 doi: 10.1093/jjco/hyq167 – ident: e_1_2_8_23_1 doi: 10.1038/aja.2010.42 – ident: e_1_2_8_4_1 doi: 10.1002/cncr.28485 – ident: e_1_2_8_7_1 doi: 10.1002/ijc.23500 – ident: e_1_2_8_9_1 doi: 10.1016/j.urology.2004.05.024 – ident: e_1_2_8_3_1 – ident: e_1_2_8_10_1 doi: 10.1016/j.urology.2004.04.014 – ident: e_1_2_8_25_1 doi: 10.1111/j.1464-410X.2006.06201.x – ident: e_1_2_8_21_1 doi: 10.1007/s00345-015-1621-5 – ident: e_1_2_8_8_1 doi: 10.1016/j.juro.2012.06.046 – ident: e_1_2_8_24_1 doi: 10.1016/j.urology.2008.01.026 – ident: e_1_2_8_13_1 – ident: e_1_2_8_2_1 – ident: e_1_2_8_15_1 doi: 10.1016/j.urolonc.2005.09.003 – ident: e_1_2_8_6_1 doi: 10.3322/caac.21254 – ident: e_1_2_8_14_1 doi: 10.1016/S0090-4295(99)00461-6 – ident: e_1_2_8_12_1 – ident: e_1_2_8_16_1 doi: 10.1002/cncr.27379 – ident: e_1_2_8_18_1 doi: 10.1590/S1677-5538.IBJU.2014.03.04 – ident: e_1_2_8_11_1 doi: 10.1056/NEJMoa1503747 – ident: e_1_2_8_26_1 doi: 10.7150/ijbs.8974 – ident: e_1_2_8_20_1 doi: 10.1111/j.1442-2042.2011.02895.x – ident: e_1_2_8_17_1 doi: 10.1186/s13014-015-0470-0 – volume: 39 start-page: 466 year: 2010 ident: e_1_2_8_22_1 article-title: Incidence, mortality and 5‐year relative survival ratio of prostate cancer among Chinese residents in Singapore from 1968 to 2002 by metastatic staging publication-title: Ann Acad Med Singapore. doi: 10.47102/annals-acadmedsg.V39N6p466 – ident: e_1_2_8_5_1 doi: 10.1016/j.eururo.2015.11.005 |
| SSID | ssj0007253 |
| Score | 2.4733832 |
| Snippet | BACKGROUND
Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about... Among patients diagnosed with distant, de novo, metastatic prostate cancer, Asian men have a superior outcome compared with men of other races. Furthermore,... Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the... BACKGROUND Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1536 |
| SubjectTerms | Aged Alaska Natives Androgen Antagonists - therapeutic use Androgens Antineoplastic Agents - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Asian Asian people Black or African American Black people Cancer chemotherapy Confidence intervals Deprivation Disease-Free Survival Docetaxel Epidemiology Ethnicity Health risk assessment Hispanic or Latino Hispanic people Humans Indians, North American Male Men Metastases Metastasis Minority & ethnic groups Native Americans Native Hawaiian or Other Pacific Islander Neoplasm Metastasis Neoplasm Staging Oncology Proportional Hazards Models Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - ethnology Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Race Races Retrospective Studies SEER Program Statistical tests survival Survival Rate Target markets Taxoids - therapeutic use Therapy Treatment Outcome White People |
| Title | Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.30503 https://www.ncbi.nlm.nih.gov/pubmed/28055108 https://www.proquest.com/docview/1920467832 https://www.proquest.com/docview/1855788697 https://www.proquest.com/docview/1897384134 https://pubmed.ncbi.nlm.nih.gov/PMC5400707 |
| Volume | 123 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPVRcoLxTCjKCC4hsvX4kXokLWqgKUnuoqLQXiGzH0VYFp9rNHuDUn9Df2F_C2MlmWYoqwc2KJ_JrZvyNH58BXjpmmKjKPMWpxaYiwwDF6KFKq5FxsrS8VPHphMOj7OBEfJrIyQa8Xd6Fafkh-gW3YBnRXwcD12a-tyINtd7OBjzQmaADHvIsEOe_P15xR-Wso6CkKpWCT3puUra3-nV9NroGMa-flPwdwcYpaP8OfFlWvj15cjZYNGZgf_7B6_i_rduG2x02Je9aZboLG87fg63Dbvf9Pnz9GK9Ukroirpl6_Nr8ILUniCFJvWiwCBfyvjtPwvIuJhodLiyd2jdkiti49u7q4nIejswHJ0vOw40TxLrEBtWbPYCT_Q-fxwdp9z5DaoUa8lQxKwQtGRUltZba3EkMd0cVN2GZ0uS6pJg0whkMagxDiUxi9II6g6DSGcUfwqbHoh8D4ZnWssoQGyFEUiOrtdDMSJMj_rC5Ngm8Wo5TYTvy8vCGxreipV1mReiwInZYAi962fOWsuOvUrvL4S46s50XCHcpzhzo5RJ43mejwYVdFO1dvUAZJdHLKazrTTKjnCvEByKBR60G9VVhiiJKpSqBfE23eoFA-L2e40-nkfhbisjOlMDrqDo3tK4YH42PY2rnX4SfwC0WYEs80LkLm81s4Z4i6GrMs2hcvwCqECrM |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB5BkYBL-aehBYzgAmq2qeMk3iNaqLbQ3UPVSnsish1HW9E61W72ACcegWfkSTrjpFmWokpws-KJ_Ddjf2OPPwO8sVxzURZZiEuLCUWKDopWuzIs-9omhYkL6Z9OGI3T4bH4NEkmbWwO3YVp-CG6DTeyDD9fk4HThvTOkjXUODPrxcRnchNuCUQa5Ht9OFyyR2W8JaGMZJiIeNKxk_Kd5b-r69EVkHk1VvJ3DOsXob17zUurc89dSLEnX3uLWvfM9z-YHf-7ffdhvYWn7H2jTw_ghnUP4faoPYB_BF_2_a1KVpXM1lOHX-tvrHIMYSSrFjWWYSnvzDpGO7yYqBXdWTox22yK8Lhy9tePn3OKmqd5lp3TpROEu8yQ9s0ew_Hex6PBMGyfaAiNkLtxKLkRIip4JIrImMhkNkGPt1_GmnYqdaaKCJNaWI1-jeYokSbowKDaIK60WsZPYM1h0RvA4lSppEwRHiFKkn2jlFBcJzpDCGIypQN4ezlQuWn5y-kZjdO8YV7mOXVY7jssgNed7HnD2vFXqa3L8c5by53niHgjXDxwogvgVZeNNkcHKcrZaoEyMsGJTmJdr5PpZ7FEiCACeNqoUFcVLiMEqpEMIFtRrk6AOL9Xc9zJ1HN_J8ITNAXwzuvONa3LB-PBoU89-xfhl3BneDQ6yA_2x5834S4nFOPjO7dgrZ4t7HPEYLV-4S3tAjqWLus |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Pb9MwFMefxpAmLjB-bYEBRnABkc5z7MSVuKBCtQGr0MSkXlhkO446AU7VpQc48Sfsb-Qv4dlJU8rQJLhZ8YtiJ-_ZHzv21wBPLdOMl0UWY9diYp7iAEWrPRmXfW1FYZJChqMTDkfp_jF_OxbjNXi52AvT6EN0E24-MkJ77QN8WpS7S9FQ48ysl3g5kytwlaeIEh6JjpbiURlrNSipjAVPxp04Kdtd3rvaHV1gzItLJX9H2NAHDW_Ap0Xpm6Unn3vzWvfM9z-EHf-3eptwvYVT8qrxppuwZt0t2Dhsf7_fhpODsKeSVCWx9cTh1fobqRxBiCTVvMZHWJ_31Tri53cxUSu_Y-nUvCAThOPK2Z8_zs_8mnnfypKp33KCsEuM973ZHTgevvk42I_bAxpiw-VeEktmOKcFo7ygxlCTWYHj3X6ZaD9PqTNVUExqbjWOajRDi1Tg8AWdBqnSapnchXWHj94GkqRKiTJFOEJGkn2jFFdMC50hgJhM6QieLb5Tblr1cn-Ixpe80V1muX9heXhhETzpbKeNZsdfrXYWnztv4_YsR96l2HVgMxfB4y4bI87_RlHOVnO0kQKbOYllvcymnyUSAYFHsNV4UFcUJiliKpURZCu-1Rl4xe_VHHc6Ccrfggd5pgieB9e5pHb5YDQ4Cql7_2L8CDY-vB7m7w9G7-7DNeYRJizu3IH1eja3DxDAav0wxNkvlTstmg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+ethnicity+on+the+outcome+of+men+with+metastatic%2C+hormone%E2%80%90sensitive+prostate+cancer&rft.jtitle=Cancer&rft.au=Bernard%2C+Brandon&rft.au=Muralidhar%2C+Vinayak&rft.au=Chen%2C+Yu%E2%80%90Hui&rft.au=Sridhar%2C+Srikala+S.&rft.date=2017-05-01&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=123&rft.issue=9&rft.spage=1536&rft.epage=1544&rft_id=info:doi/10.1002%2Fcncr.30503&rft.externalDBID=10.1002%252Fcncr.30503&rft.externalDocID=CNCR30503 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |